Hologic Inc. signed an agreement to acquire Gynesonics Inc. for $350 million. The acquisition will significantly boost Hologic’s revenues from surgical gynecology and provide an option not met by the company’s current portfolio of products.
Tokyo-based Olympus Corp. launched a new video imaging platform called Visera S (OTV-S500) in Europe and select Asian countries September 2024 while advancing more rollouts for the product worldwide.
By treating mice with antifibrotic drugs, researchers were able to stave off functional decline of the ovaries. Six weeks of systemic treatment with the antifibrotic pirfenidone, which is approved for the treatment of idiopathic pulmonary fibrosis, in early middle age improved both the morphology and the endocrine function of the animals’ ovaries at 1 year of age.
The map of the human brain is not a static image of the cellular architecture of the central nervous system (CNS). Throughout life, all living beings are born, develop and age. The brain of pregnant mothers reflects a dynamic that modifies this general picture. A collaboration of scientists from the University of California has studied the changes in the adult brain during pregnancy and observed that a large part of it adapts during the development of the fetus.
Femasys Inc. checked off a box on the way to launch of its Fembloc non-surgical birth control method with U.S. FDA clearance of Femchec. An enhanced version of the Femvue product used to diagnose fallopian tube abnormalities, Femchec enables confirmation of successful blockage of the fallopian tubes to prevent pregnancy without use of radiation.
Germitec SA received U.S. FDA de novo clearance for Chronos, its chemical-free, ultraviolet-C-based disinfection device for endocavitary and external ultrasound probes. The technology will help to protect patients and aid health care professionals in tackling cross-contaminations in U.S. hospitals, Vincent Gardès, CEO of Germitec, told BioWorld.
In what represents the first patenting from Munich, Germany-based Meliodys Medical UG, its co-founder and chief executive officer Simone Sabbione describes their development of a hormone-free, local pain management approach for treating dysmenorrhea, which aims to address the condition while minimizing the occurrence of side effects.
In Ciconia Medical Inc.’s first patenting, the company’s founder and CEO, Roni Cantor-Balan, describes the development of a cervical measurement device for childbirth progress monitoring that replaces the manual vaginal examinations undertaken during labor.
Recurrent spontaneous abortion (RSA), also known as recurrent miscarriage, is a disorder related to pregnancy defined as two or more pregnancy losses during the first trimester. It affects about 2%-5% of couples trying to conceive. Chinese researchers have investigated the potential involvement of Cbl proto-oncogene like 1 (CBLL1) in RSA, since CBLL1 has been reported to vary with the menstrual cycle in the endometrium.
After decades of being woefully under-diagnosed and all but ignored by the biotech and pharma industry, recent advances in understanding its complex etiology could be opening the way to new treatments for endometriosis. Impetus is coming from (modest) increases in funding for basic research, such as the Biden administration’s $200 million for women’s health research and NIH grants under an ‘Advancing cures and therapies and ending endometriosis diagnostic delays’ call announced in March of this year.
RSS
